The British Journal of Cardiology

This site is intended for UK healthcare professionals

Sponsorship statement:
Novartis Pharmaceuticals UK Ltd has provided OmniaMed Communications Ltd with an arm’s length sponsorship towards the development of the British Journal of Cardiology Masterclasses in Heart Failure.

Masterclass: Foundational drugs: Evidence-based prescribing in heart failure with reduced ejection fraction (HFrEF)

8 November 2023
Available for 1 CPD point(s)


Watch Professor Paul Kalra and Professor John McMurray provide an overview of the treatment changes which have taken place in recent years and transformed the management of HFrEF. They also outline strategies to improve the management of HFrEF, and the management of high-risk patients and those with chronic kidney disease.

Professor Paul Kalra Professor of Cardiology, Portsmouth Hospitals NHS Trust, UK
Professor John McMurray Professor of Medical Cardiology, University of Glasgow, UK

Learning objectives
  • The main changes in HFrEF therapy in recent years
  • The role of SGLT2 inhibitors and MRAs in the management of HFrEF
  • Working with patients and healthcare professionals to improve the management of HFrEF
  • Management of HFrEF in people with chronic kidney disease
  • Management of high-risk HFrEF patients
Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.


1. McMurray JJV, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol 2022;45 Suppl 1(Suppl 1):S26–S30.

2. Shen L, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J 2022;43:2573–87.

3. Zannad F, McMurray JJV, Krum H; EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.

4. Matsumoto S, Kondo T, Jhund PS, et al. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 2023;82:1080–91.

5. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–e1032.

6. (2023). Aldosterone receptor antagonists or mineralocorticoid receptor antagonist (MRAs). Available at:,urine%20and%20are%20weak%20diuretics. (accessed October 2023)

7. National Cardiac Audit Programme (2023). National Heart Failure Audit 2023 Summary Report (2021/22 data). Available at: (accessed October 2023)

8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.


Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.